Intelligent Bio Solutions (INBS) Q4 2026 earnings summary

Executive summary

• Achieved record annual revenue of $4.2 million for fiscal 2026, a 38% year-over-year increase, driven by a 22% expansion in reader installed base and 35% growth in consumable cartridges.

• Gross profit margin expanded to 48.63%, up 778 basis points year-over-year, reflecting improved unit economics and operational efficiencies.

• Active customer base reached 502 as of June 30, 2026, with commercial traction across safety-critical industries and international markets.

• Substantial progress made toward FDA 510(k) clearance, with all clinical data collection completed and submission on track for the second half of 2026.

Financial highlights

• Total revenue grew to $4,215,175, up from $3,052,532 year-over-year.

• Gross profit increased 64% to $2,049,994, with gross margin rising from 40.85% to 48.63%.

• Reader installed base reached 1,886 units, up 22% from the prior year.

• Total consumable cartridges sold rose 35% to 106,500 units.

• Net loss attributable to the company was $(12,430,975), compared to $(10,568,733) in the prior year.

Outlook and guidance

• Focus for fiscal 2027 includes sustaining gross margin expansion, accelerating commercial growth, and advancing FDA regulatory program for U.S. market entry.

• FDA 510(k) submission is on track for the second half of calendar 2026, targeting entry into the U.S. drug screening market.